A Study of Dry Mouth and Gastrointestinal Disorders in Patients Taking Antidepressant
- Author:
Yeong-Jin HEO
1
;
Chan-Mo YANG
;
Hye-Jin LEE
;
Sang-Yeol LEE
;
Seung-Ho JANG
Author Information
- Publication Type:Original Article
- From: Mood and Emotion 2022;20(1):15-22
- CountryRepublic of Korea
- Language:English
-
Abstract:
Background:The purpose of this study was to identify the characteristics of dry mouth and gastrointestinal (GI) disorders in antidepressant patients.
Methods:The study included 103 antidepressant-taking patients. Antidepressants were classified according to their mode of action. The GI disorders were investigated using the medical records of the patients. The Patient Health Questionnaire-15 and a questionnaire for assessing dry mouth symptoms were used in this study.
Results:The score for “overall discomfort due to dry mouth in daily life” (31.72±33.82), “dry mouth at night or in the morning” (47.86±35.87), and “dry mouth during the day” (39.83±31.67) were slightly higher than “discomfort in chewing or swallowing foods”. According to somatization severity, the mean values were 116.36±113.34 in the mild, 213.18±136.98 in the moderate, and 277.59±201.44 in the severe, the between-group difference was significant (F=10.294, p<0.001). According to the class of antidepressants, the mean score was 180.00±147.5 for vortioxetine, 194.25±169.33 for selective serotonin reuptake inhibitors (SSRIs), 223.61±156.70 for serotonin and norepinephrine reuptake inhibitors (SNRIs), 75.00±57.00 for norepinephrine dopamine reuptake inhibitors (NDRIs), 201.67±174.66 for Nassau, and 116.67±132.03 for agomelatine. A total of 67 (65.0%) patients had at least one GI disorder.
Conclusion:The study findings are expected to help increase medication compliance in antidepressant patients by better controlling the side effects experienced by the patients.
